Skip Navigation

Profile

Waldemar Debinski, M.D., Ph.D.Wake Forest School of Medicine

Waldemar Debinski, M.D., Ph.D.

Center of Excellence Director,
Professor,


Contact Information

Academic: 336-713-7634 | Department: 336-716-2011

Email: debinski@wakehealth.edu

Media Medical Expert »

Education & Training

  • M.D., Academy Med Warsaw-Poland, 1981
  • Ph.D., Mcgill University Med-Canada, 1989
Waldemar Debinski, M.D., Ph.D.

Waldemar Debinski, M.D., Ph.D.

Center of Excellence Director, Brain Tumor Center of Excellence
Professor, Cancer Biology
Microbiology & Immunology
Neurosurgery

Research Interests

Brain Neoplasms; Glioblastoma; Ephrin-A1; Receptor, EphA2; Interleukin-13 Receptor alpha2 Subunit
More »

Contact Information

Academic: 336-713-7634 | Department: 336-716-2011

Email: debinski@wakehealth.edu

Media Medical Expert »

Recent Publications

Use of non-ionizing electromagnetic fields for the treatment of cancer. Jimenez H, Blackman C, Lesser G, Debinski W, Chan M, Sharma S, Watabe K, Lo HW, Thomas A, Godwin D, Blackstock W, Mudry A, Posey J, O'Connor R, Brezovich I, Bonin K, Kim-Shapiro D, Barbault A, Pasche B.. Front Biosci (Landmark Ed). 2018;23():284-297.

Outcomes for anaplastic glioma treated with radiation therapy with or without concurrent temozolomide. McTyre E, Lucas JT, Helis C, Farris M, Soike M, Mott R, Laxton AW, Tatter SB, Lesser GJ, Strowd RE, Lo HW, Debinski W, Chan MD.. Am J Clin Oncol. 2017;():.

Peptide-based PET imaging of the tumor restricted IL13RA2 biomarker. Sai KK, Sattiraju A, Almaguel FG, Xuan A, Rideout S, Krishnaswamy RS, Zhang J, Herpai DM, Debinski W, Mintz A.. Oncotarget. 2017;8(31):.

Expression and activity of the urokinase plasminogen activator system in canine primary brain tumors. Rossmeisl JH, Hall-Manning K, Robertson JL, King JN, Davalos RV, Debinski W, Elankumaran S.. Onco Targets Ther. 2017;10():2077-2085.

IL13RA2 targeted alpha particle therapy against glioblastomas. Sattiraju A, Solingapuram Sai KK, Xuan A, Pandya DN, Almaguel FG, Wadas TJ, Herpai DM, Debinski W, Mintz A.. Oncotarget. 2017;8(26):.

Combined inhibition of AKT and HSF1 suppresses breast cancer stem cells and tumor growth. Carpenter RL, Sirkisoon S, Zhu D, Rimkus T, Harrison A, Anderson A, Paw I, Qasem S, Xing F, Liu Y, Chan M, Metheny-Barlow L, Pasche BC, Debinski W, Watabe K, Lo HW.. Oncotarget. 2017;8(43):73947-63.

A multivalent protein for immune checkpoint inhibition at the tumor site [abstract]. Debinski W, Rodriguez A, Herpai DM, Ahlers S.. Neuro Oncol. 2017;19(Suppl 3):49.

In situ detection of hypoxia inducible factor 2 alpha in malignant gliomas [abstract]. Renfrow JJ, Strowd RE, Huang Y, Herpai D, Mott RT, Wong T, Lesser GJ, Debinski W.. Neuro Oncol. 2017;19(Suppl 3):57.

Tolerability and initial efficacy of convection-enhanced delivery of combinatorial IL-13RA2 and EPHA2 targeted cytotoxins to dogs with spontaneous intracranial malignant gliomas [abstract]. Rossmeisl JH, Herpai D, Robertson JL, Dickinson PJ, Tatter SB, Debinski W.. Neuro Oncol. 2017;19(Suppl 3):56.

A single pharmaceutic agent for molecular resection of glioblastoma [abstract]. Sonawane P, Herpai D, Ferluga S, Tatter SB, Debinski W.. Neuro Oncol. 2017;19(Suppl 3):56.

Enhancing irreversible electroporation by manipulating cellular biophysics with a molecular adjuvant. Ivey JW, Latouche EL, Richards ML, Lesser GJ, Debinski W, Davalos RV, Verbridge SS.. Biophys J. 2017;113(2):472-480.

PET imaging validation of an IL13RA2-binding peptide as a targeting platform against cancer [abstract]. Sai KKS, Almaguel F, Sattiraju A, Rideout S, Ang X, Krishnaswamy R, Cartwright J, van Nguyen, Herpai D, Waldemar D, Mintz A.. J Nucl Med. 2017;58(Suppl 1):56.

Treatment of brain metastases of lung cancer in the era of precision medicine. Haughton ME, Chan MD, Watabe K, Bonomi M, Debinski W, Lesser GJ, Ruiz J.. Front Biosci (Elite Ed). 2016;8():219-232.

Pseudo progression identification of glioblastoma with dictionary learning. Zhang J, Yu H, Qian X, Liu K, Tan H, Yang T, Wang M, Li KC, Chan MD, Debinski W, Paulsson A, Wang G, Zhou X.. Comput Biol Med. 2016;73():94-101.

The applications of the novel polymeric fluoropyrimidine F10 in cancer treatment: current evidence. Gmeiner WH, Debinski W, Milligan C, Caudell D, Pardee TS.. Future Oncol. 2016;12(17):2009-2020.

Simultaneous targeting of Eph receptors in glioblastoma. Ferluga S, Tome CM, Herpai DM, D'Agostino R, Debinski W.. Oncotarget. 2016;7(37):59860-76.

Canine butterfly glioblastomas: a neuroradiological review. Rossmeisl JH, Clapp K, Pancotto TE, Emch S, Robertson JL, Debinski W.. Front Vet Sci. 2016;3():40.

Genomic predictors of imaging response and survival in glioblastoma [abstract]. Soike M, McTyre E, Holmes JA, Paulsson AK, Miller L, Lesser GJ, Strowd RE, Johnson A, Lo HW, Laxton AW, Tatter SB, Debinski W, Chan MD.. Int J Radiat Oncol Biol Phys. 2016;96(2 Suppl):E121-E122.

Local control of brain metastases after stereotactic radiosurgery: the impact of whole brain radiotherapy and treatment paradigm. Hughes RT, Black PJ, Page BR, Lucas JT, Qasem SA, Watabe K, Ruiz J, Laxton AW, Tatter SB, Debinski W, Chan MD.. J Radiosurg SBRT. 2016;4(2):89-96.

Selection of a novel aptamer against vitronectin using capillary electrophoresis and next generation sequencing. Stuart CH, Riley KR, Boyacioglu O, Herpai DM, Debinski W, Qasem S, Marini FC, Colyer CL, Gmeiner WH.. Mol Ther Nucleic Acids. 2016;5(11):e386.

Impact of timing of radiotherapy in patients with newly diagnosed glioblastoma. Randolph DM II, McTyre ER, Paulsson AK, Holmes JA, Hinson WH, Lesser GJ, Strowd R, Lo HW, Laxton AW, Tatter SB, Debinski W, Chan MD.. Clin Neurol Neurosurg. 2016;151():73-78.

The anti-proliferative effects of RF EMF amplitude-modulated (AM RF EMF) at tumor specific frequencies on glioblastoma cells [abstract]. Jimenez H, Wang MH, Sharma S, Herpai D, Lesser GJ, Debinski W, Costa F, Barbault A, Blackman C, Pasche B.. Neuro Oncol. 2016;18(Suppl 6):68.

Nicotinamide phosphoribosyltransferase (NAMPT) is required to maintain cellular metabolism in glioblastoma [abstract]. Wheeler F, Lesser GJ, Herpai D, Debinski W, Kridel S.. Neuro Oncol. 2016;18(Suppl 6):101.

Mechanisms regulating glioma invasion. Paw I, Carpenter RC [sic] [Carpenter RL], Watabe K, Debinski W, Lo HW.. Cancer Lett. 2015;362(1):1-7.

The gain-of-function truncated GLI1 (TGLI1) promotes glioblastoma angiogenesis by direct upregulation of VEGF-C and TEM7 expression [abstract]. Carpenter RL, Paw I, Sirkisoon S, Xing F, Gibo D, Watabe K, Debinski W, Lo HW.. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research (AACR); 2015 Apr 18-22; Philadelphia (PA). 2015;():A4165.

Impact of systemic targeted agents on the clinical outcomes of patients with brain metastases. Johnson AG, Ruiz J, Hughes R, Page BR, Isom S, Lucas JT, McTyre ER, Houseknecht KW, Ayala-Peacock DN, Bourland DJ, Hinson WH, Laxton AW, Tatter SB, Debinski W, Watabe K, Chan MD.. Oncotarget. 2015;6(22):18945-55.

Neurosurgical techniques for disruption of the blood-brain barrier for glioblastoma treatment. Rodriguez A, Tatter SB, Debinski W.. Pharmaceutics. 2015;7(3):175-187.

The gain-of-function GLI1 transcription factor TGLI1 enhances expression of VEGF-C and TEM7 to promote glioblastoma angiogenesis. Carpenter RL, Paw I, Zhu H, Sirkisoon S, Xing F, Watabe K, Debinski W, Lo HW.. Oncotarget. 2015;6(26):22653-65.

Genomic predictors of patterns of progression in glioblastoma and possible influences on radiation field design. Holmes JA, Paulsson AK, Page BR, Miller LD, Liu W, Xu J, Hinson WH, Lesser GJ, Laxton AW, Tatter SB, Debinski W, Chan MD.. J Neurooncol. 2015;124(3):447-453.

Frame-based stereotactic biopsy of canine brain masses: technique and clinical results in 26 cases. Rossmeisl JH, Andriani RT, Cecere TE, Lahmers K, LeRoith T, Zimmerman KL, Gibo D, Debinski W.. Front Vet Sci. 2015;2():20.

Invited review-neuroimaging response assessment criteria for brain tumors in veterinary patients. Rossmeisl JH Jr, Garcia PA, Daniel GB, Bourland JD, Debinski W, Dervisis N, Klahn S.. Vet Radiol Ultrasound. 2014;55(2):115-132.

Selective anti-tumor activity of the novel fluoropyrimidine polymer F10 towards G48a orthotopic GBM tumors. Gmeiner WH, Lema-Tome C, Gibo D, Jennings-Gee J, Milligan C, Debinski W.. J Neurooncol. 2014;116(3):447-454.

Limited margins using modern radiotherapy techniques does not increase marginal failure rate of glioblastoma. Paulsson AK, McMullen KP, Peiffer AM, Hinson WH, Kearns WT, Johnson AJ, Lesser GJ, Ellis TL, Tatter SB, Debinski W, Shaw EG, Chan MD.. Am J Clin Oncol. 2014;37(2):177-181.

Comparison of clinical outcomes and genomic characteristics of single focus and multifocal glioblastoma. Paulsson AK, Holmes JA, Peiffer AM, Miller LD, Liu W, Xu J, Hinson WH, Lesser GJ, Laxton AW, Tatter SB, Debinski W, Chan MD.. J Neurooncol. 2014;119(2):429-435.

Does delay of start of radiation affect clinical outcomes of glioblastoma [abstract]. Randolph DM, Peiffer AM, Paulsson AK, Hinson W, Laxton AW, Tatter SB, Debinski W, Chan MD.. Int J Radiat Oncol Biol Phys. 2014;90(Suppl 1):S295.

Genomic predictors of infield and marginal failure for glioblastoma treated with concurrent radiation therapy and temozolomide: a step towards personalized radiation fields? [abstract]. Holmes JA, Paulsson A, Peiffer AM, Miller LD, Xu J, Hinson WH, Lesser GJ, Tatter SB, Debinski W, Chan MD.. Int J Radiat Oncol Biol Phys. 2014;90(Suppl 1):S291-S292.

Functional presence of M2 macrophage markers in GBM tumor cells [abstract]. Debinski W, Rodriguez A, Gibo D, Tatter SB, Mott R, Lively M, Miller L, Seals DF.. Neuro Oncol. 2014;16(Suppl 3):.

Ephs and ephrins in malignant gliomas. Ferluga S, Debinski W.. Growth Factors. 2014;32(6):190-201.

EphA3 receptor is a molecular target expressed in multiple compartments of GBM [abstract]. Ferluga S, Gibo D, Debinski W.. Neuro Oncol. 2014;16(Suppl 5):v25.

Molecular signature of cancer. Debinski W, Wykosky J, Gibo D, inventors; Wake Forest University Health Sciences, assignee.. United States patent US 8,343,461. 2013 Jan 1. 2013;():.

Multi-level specific targeting of cancer cells. Debinski W, Pandya H, Gibo D, inventors; Wake Forest University Health Sciences, assignee.. United States patent US 8,362,207. 2013 Jan 29. 2013;():.

Biological and structural characterization of glycosylation on Ephrin-A1, a preferred ligand for EphA2 receptor tyrosine kinase. Ferluga S, Hantgan R, Goldgur Y, Himanen JP, Nikolov DB, Debinski W.. J Biol Chem. 2013;288(25):18448-57.

New agents for targeting of IL-13RA2 expressed in primary human and canine brain tumors. Debinski W, Dickinson P, Rossmeisl JH, Robertson J, Gibo DM.. PLoS One. 2013;8(10):e77719.

Nucleus-targeted doxorubicin as a potential therapy for glioblastoma [abstract]. Choi YA, Pandya H, Gibo DM, Fokt I, Priebe W, Debinski W.. Neuro Oncol. 2013;15(Suppl 3):40.

Targeting (klaklak)(2), a pro-apoptotic peptide to GMB cells [abstract]. Choi YA, Pandya H, Gibo DM, Debinski W.. Neuro Oncol. 2013;15(Suppl 3):69.

Eph receptor A3 is a molecular therapeutic target for the treatment of glioblastoma [abstract]. Ferluga S, Tome CL, Debinski W.. Neuro Oncol. 2013;15(Suppl 3):43.

Antigens characteristic of M2 type pro-inflammatory macrophages are present on GBM tumor cells [abstract]. Debinski W, Choi YA, Gibo DM.. Neuro Oncol. 2013;15(Suppl 3):63.

Therapeutic efficacy of an optimized quadruply mutated IL13-based bacterial cytotoxin in an orthotopic murine glioma model [abstract]. Nguyen V, Zhu D, Conyers JM, Debinski W, Mintz A.. Cancer Res. 2013;73(8 Suppl 1):A2150.

An interleukin 13 receptor alpha 2-specific peptide homes to human glioblastoma multiforme xenografts. Pandya H, Gibo DM, Garg S, Kridel S, Debinski W.. Neuro Oncol. 2012;14(1):6-18.

Ephs and ephrins in cancer: ephrin-A1 signalling. Beauchamp A, Debinski W.. Semin Cell Dev Biol. 2012;23(1):109-115.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Professor, Cancer Biology

Waldemar Debinski, M.D., Ph.D.

Waldemar Debinski, M.D., Ph.D.

Center of Excellence Director, Brain Tumor Center of Excellence
Professor, Cancer Biology
Microbiology & Immunology
Neurosurgery

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
Six Wake Forest Baptist Specialties Earn U.S. News RankingsComprehensive Cancer Centers National Designation is Renewed2017-2018 Best DoctorsMagnet Hospital RecognitionJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.

© Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157. All Rights Reserved.